Stoke Therapeutics Inc at JPMorgan Healthcare Conference Transcript
My name is Jess Fye. I'm one of the large-cap biotech analyst at JPMorgan, and we're delighted to be continuing the conference today with Stoke. A little different format than in past years. We're not switching rooms for Q&A. We're going to go right into the Q&A session in this room after the presentation starts. (Conference Instructions)
So with that out of the way, let me turn it over to Stoke's CEO, Ed Kaye.
Well, good morning, everyone. I'm Edward Kaye, and I am CEO, Stoke Therapeutics. I will be making some forward-looking statements this morning. So please refer to our full SEC documents.
To put it simply for Stoke, we're a company that really is aiming to upregulate protein expression. And we're focused on really treating the underlying cause of severe genetic diseases. We have a number of targets that we're going after. And really what we're trying to be is really first-in-class in disease-modifying. And again, focused on diseases where
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
